RARRES2 and Cirrhosis: Collectively, these studies identify low circulating chemerin as a consistent feature of advanced cirrhosis, reflecting hepatic dysfunction and portal hypertension, and suggesting potential, but still preliminary utility for risk assessment in end-stage liver disease (Figure 6).